By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MedImmune 

One MedImmune Way

Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-398-0000 Fax: 301-398-9000


SEARCH JOBS

MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.

With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.

Key Statistics


Email:
Ownership: Public

Web Site: MedImmune
Employees: 3,000
Symbol: AZN
 



Industry
Biotechnology






Company News
MedImmune (AZN) Receives Fast Track Designation From FDA For Development Of MEDI3902 For Prevention Of Nosocomial Pneumonia 9/23/2014 10:42:42 AM
Allozyne, Inc. Sold For Scrap As MedImmune (AZN) Snaps Up Rights 9/19/2014 6:50:12 AM
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014 6:34:46 AM
AIMM Therapeutics’ Partner MedImmune (AZN) Starts Clinical Studies With RSV Antibody 7/2/2014 10:50:14 AM
Ventana Medical Systems, Inc. (VMSI) And MedImmune (AZN) Collaborate To Develop A Custom PD-L1 Assay For Immunotherapy Clinical Trials 6/4/2014 9:17:21 AM
AstraZeneca PLC (AZN) And MedImmune (AZN) Release: New Study Reveals Significant Burden Of RSV Disease Among U.S. Preterm Infants Born At 32-35 Weeks 6/3/2014 10:09:39 AM
AstraZeneca PLC (AZN)’s MedImmune (AZN) Presents Encouraging Immunotherapy Data at American Society of Clinical Oncology 2014 6/3/2014 9:49:35 AM
ADC Therapeutics To Move Antibody Drug Conjugate ADCT-401 For Prostate Cancer Into Human Clinical Trials With Partner MedImmune (AZN) 5/19/2014 8:39:39 AM
Incyte Corporation (INCY) And MedImmune (AZN) Announce Collaboration On Immuno-Oncology Combination Clinical Trial 5/14/2014 9:08:57 AM
MedImmune (AZN) Seeks Job Security Guarantee From Pfizer Inc. (PFE) 5/13/2014 7:04:07 AM
12345678910...
//-->